Why the study?
Does the novel aldosterone synthase inhibitor LCI699 reduce blood pressure in patients with primary hypertension?
Does the novel aldosterone synthase inhibitor LCI699 reduce blood pressure in patients with primary hypertension?
The novel aldosterone synthase inhibitor LCI699 effectively lowers blood pressure in primary hypertension, though it may blunt cortisol release in some patients.
Supports aldosterone synthase inhibition as a new BP-lowering strategy in primary hypertension; first RCT evidence for this mechanism.
Aldosterone synthase inhibition with LCI699 significantly lowered clinic and ambulatory blood pressure. A minority of subjects developed blunted adrenocorticotropic hormone-stimulated release of cortisol. These results support additional research to evaluate use of aldosterone synthase inhibition in primary hypertension and/or patients characterized by aldosterone excess. Clinical Trial Registration- URL: http://www.clinicaltrials.gov. Unique identifier: NCT00758524.
No takes yet. Share an insight, caveat, or question.
Calhoun et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: